The Title VIII Nursing Workforce Reauthorization Act of 2025 reauthorizes federal funding for nursing education programs through 2030, increasing annual appropriations to support nurse training and workforce development. It expands grant eligibility to include nurse practitioner, nurse-midwifery, nurse anesthesia, and clinical nurse specialist programs, while requiring funds to cover clinical education costs like preceptor fees. The bill directs grants toward technology such as simulation labs, telehealth, and virtual training to modernize nursing education, and mandates partnerships with healthcare facilities to create clinical training opportunities. Additionally, it updates program requirements to include support for survivors of sexual assault and focuses on increasing nursing faculty and student enrollment to address nationwide nursing shortages.
HR 729, the Teleabortion Prevention Act of 2025, prohibits healthcare providers from administering chemical abortions (using drugs to terminate pregnancy) via telehealth or remote means without being physically present during the procedure. It requires providers to physically examine the patient, be present at the location of the abortion, and schedule a follow-up visit within 14 days. The bill directly affects healthcare providers offering telemedicine abortion services, imposing fines up to $1,000 or up to 2 years in prison for violations. Exceptions apply for life-threatening medical emergencies, and the law explicitly excludes treatment for verified ectopic pregnancies. This bill targets the remote provision of abortion drugs, making in-person provider presence mandatory for such procedures.
HR 3108, the RPM Access Act, increases Medicare reimbursement for remote patient monitoring (RPM) in rural areas by setting a minimum reimbursement floor of 100% for practice expenses and malpractice costs starting in 2026. It requires that RPM services include real-time physician availability to address health issues, use data systems compatible with electronic health records, and mandates providers to report data on cost savings and adherence to medications. The bill directly affects rural Medicare beneficiaries with chronic conditions like heart failure and diabetes, as well as healthcare providers delivering RPM services in underserved rural communities. It also requires a 5-year report to Congress analyzing cost savings from RPM use, including reduced hospitalizations and medication adherence. The law aims to improve access to RPM in rural areas where healthcare shortages are most severe.
S 1074, the *Agricultural Access to Substance Use Disorder Treatment and Mental Health Care Act of 2025*, mandates a study on mental health and substance use disorder care access for farmers, ranchers, and agricultural workers. The Comptroller General will examine rural availability of specialized providers, barriers like cost or geography, and effective programs (such as telehealth or cultural training) to inform future policy. The study’s findings will be submitted to key congressional committees and federal agencies, including Agriculture and Health and Human Services, to guide potential improvements in care accessibility for agricultural communities. This procedural bill does not create new programs but focuses on gathering data to address existing gaps.
This bill requires the HHS Secretary to create drug adherence guidelines aiming for 90% medication adherence among Medicare Part B and D drug users. It mandates using AI and machine learning technologies in developing these guidelines and prioritizes promoting generic and biosimilar drugs where possible. The policy directly affects Medicare beneficiaries and providers by setting a measurable adherence target for covered drugs. Key changes include new federal guidelines focused on improving medication consistency through technology and cost-effective drug options.
This bill increases Medicare reimbursement rates for rural remote patient monitoring (RPM) services by setting a minimum floor of 1.00 for practice expense and malpractice indices starting in 2026, directly benefiting rural clinics and providers in areas with health care shortages. It requires RPM providers to respond to data anomalies, share patient vitals with electronic health records, and report data to track Medicare savings. The bill mandates a two-year report analyzing cost savings from reduced hospital stays and better medication adherence among beneficiaries using RPM. These changes specifically target improving access to RPM for rural Medicare patients with chronic conditions like heart failure and diabetes.
The TREATS Act amends the Controlled Substances Act to allow telehealth evaluations as an alternative to in-person medical evaluations for prescribing certain controlled substances. Specifically, it permits one telehealth evaluation (conducted via real-time audio/video systems meeting Social Security Act standards) instead of an in-person visit when prescribing FDA-approved medications for substance use disorder treatment (schedules III-V). This directly affects healthcare providers who prescribe these medications, expanding their ability to use telehealth for initial patient assessments. The change maintains the requirement for at least one evaluation (either in-person or telehealth) while updating the process to include telehealth options for this specific treatment context.
This bill regulates healthcare platforms that help patients find providers (like online appointment directories). It prohibits these platforms from steering patients toward specific providers based on payment, requiring full disclosure of financial ties between platforms and healthcare providers. Platforms must use objective criteria for listing providers, cannot offer medical services or collect patient data improperly, and must set fair, pre-agreed compensation rates. It directly affects health tech companies operating these platforms and healthcare providers using them to connect with patients.
HR 1349, the Women’s Protection in Telehealth Act, excludes Medicare participation for providers who prescribe, administer, dispense, or furnish abortion-inducing drugs via telehealth unless they meet strict conditions. Specifically, providers must be physicians who physically examine the patient, be present in the same room during drug administration, and schedule an in-person follow-up within 14 days. The bill defines "abortion-inducing drug" as any substance used to terminate a clinically diagnosable pregnancy with knowledge it will likely cause fetal death. This directly affects Medicare-covered telehealth abortion services, requiring in-person care for such treatments rather than remote consultations. The exclusion is permanent for non-compliant providers under Medicare rules.
This bill amends the Federal Food, Drug, and Cosmetic Act to allow artificial intelligence (AI) and machine learning technologies to legally prescribe drugs under specific conditions. It requires AI systems to be both authorized by state law and approved by the FDA under sections 510(k), 513, 515, or 564. The law directly affects healthcare AI developers, providers, and patients by establishing a regulatory framework for AI-driven drug prescriptions. Key provisions define AI as a "practitioner" for prescription purposes only when meeting these two federal and state requirements. This creates a clear pathway for AI to legally prescribe drugs within existing FDA and state oversight.
